Pfizer launched ten mobile sites in four months last year by tackling tough problems early and building a template for all its brands.
Researchers said the industry closed 2012 with a mixed bag of results. The upside: more approvals than last year. The downside: projected sales for these new drugs is less.
Of the top 10 pharma companies worldwide, GlaxoSmithKline looked beyond its own pipeline for new drugs most often, signing 67 in-licensing agreements in just two years, according to a Datamonitor analysis.
In an age of accountability, where every dollar counts, Deborah Dick-Rath talks to industry insiders about how they can make a measurable difference in their marketing mix